Definium, GSK, AstraZeneca, Medicare: Readout Newsletter

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Definium’s LSD therapy has a strong performacne in a pivotal anxiety trial, drugmaker deals could gut “most-favored nation” Medicare savings, and more.

In this endless heat wave my house is now overrun with flies and I think I give up and will also become a fly. They win.

STAT+ Exclusive Story

STAT+

This article is exclusive to STAT+ subscribers

Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.

Already have an account? Log in

View All Plans

To read the rest of this story subscribe to STAT+.

Subscribe

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *